



**HAL**  
open science

## Bacterial Peptidoglycans from Microbiota in Neurodevelopment and Behavior

Ayoze Gonzalez-Santana, Rochellys Diaz Heijtz

► **To cite this version:**

Ayoze Gonzalez-Santana, Rochellys Diaz Heijtz. Bacterial Peptidoglycans from Microbiota in Neurodevelopment and Behavior. Trends in Molecular Medicine, 2020, 26, pp.729 - 743. 10.1016/j.molmed.2020.05.003 . hal-03492013

**HAL Id: hal-03492013**

**<https://hal.science/hal-03492013v1>**

Submitted on 22 Aug 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

### Bacterial Peptidoglycans from Microbiota in Neurodevelopment and Behavior

Ayoze Gonzalez Santana<sup>1</sup> and Rochellys Diaz Heijtz<sup>1,2\*</sup>

<sup>1</sup> Department of Neuroscience, Karolinska Institutet, Biomedicum, 171 77 Stockholm, Sweden

<sup>2</sup> Inserm U1239, University of Rouen Normandy, 76000 Rouen, France

\* Correspondence: [rochellys.heijtz@ki.se](mailto:rochellys.heijtz@ki.se) (R. Diaz Heijtz)

Key words: Microbiome; Peptidoglycan recognition proteins, NOD-like receptors, Placenta, Anxiety-like behavior, HPA-axis, cognition, Pregnancy.

26

27 **Abstract**

28 It is becoming increasingly recognized that the gut microbiota profoundly influences many  
29 aspects of host development and physiology, including the modulation of brain development  
30 and behavior. However, the precise molecular mechanisms and signaling pathways involved  
31 in the communication between the microbiota and the developing brain remain to be fully  
32 elucidated. Germline-encoded pattern recognition receptors that recognize conserved  
33 microbial molecular signatures, such as bacterial surface molecules (*e.g.*, peptidoglycans)  
34 have emerged as potential key regulators of gut microbiota-brain interactions. In this review,  
35 we highlight current evidence supporting multiple and essential roles for peptidoglycans and  
36 their sensing molecules well beyond innate immunity, extending to neurodevelopment and  
37 behavior. In addition, the possible implications of the peptidoglycan signaling pathway for  
38 the pathogenesis of neurodevelopmental disorders such as autism spectrum disorder is  
39 considered.

## 40 **The Gut Microbiota: A Key Regulator of Neurodevelopment and Behavior**

41 The mammalian gastrointestinal tract harbors a dynamic and complex community of  
42 microorganisms, including bacteria, archaea, fungi, and viruses—known collectively as the gut  
43 microbiota. Microbial colonization is an evolution-driven process that has provided mutual  
44 benefits to both microbes and the mammalian host. The first major exposure to a complex  
45 microbiota occurs during birth via vertical mother-to-infant microbial transmission (i.e.,  
46 when infants are exposed to their maternal vaginal, fecal and perineal microbes), and is a  
47 pivotal event early in life determining the initial assembly of the infant gut microbiota [1]  
48 (Box 1). The bacterial population is currently the most well characterized. Although the ratio  
49 between bacteria to human cells is close to one [2], the total number of bacterial genes in  
50 the collective human microbiome is estimated to be 2-20 million, exceeding the human  
51 genome by at least a factor of 100 [3, 4]. Many of these bacterial genes encode enzymes  
52 that can perform metabolic functions not achievable by the host and produce metabolites  
53 that can impact host health and disease. Over the past decades, studies have demonstrated  
54 that gut bacteria interact and perform numerous critical functions for their host, including  
55 dietary energy extraction, the production of vitamins, protection against invading gut  
56 pathogens [5, 6], as well as promoting the development and function of the immune system  
57 [1, 7]. Recent investigations have revealed that the gut microbiota exerts a broader range of  
58 effects on host physiology and development beyond the gastrointestinal tract, including the  
59 modulation of brain development and behavior [8, 9].

60

61 In a landmark study, Sudo and colleagues in 2004 showed that postnatal bacterial  
62 colonization affects the early life programming of the hypothalamic–pituitary–adrenal (HPA)  
63 axis, the central stress response system [10]. More specifically, they took advantage of germ-  
64 free (GF; devoid of bacteria throughout life) mice to assess how the absence of microbiota  
65 affects the HPA-axis response to various stress modalities. In adult GF mice, exposure to a  
66 mild restraint stress induced an exaggerated release of adrenocorticotrophic hormone (ACTH)  
67 and corticosterone compared with control mice with a normal composition of microbiota  
68 and no specific pathogens (known as specific-pathogen-free mice; SPF). The exaggerated  
69 HPA stress responses of GF mice were fully reversed through colonization with  
70 *Bifidobacterium infantis*. Several years later, Diaz Heijtz and colleagues demonstrated that  
71 the absence of microbiota profoundly affects motor activity and anxiety-like behavior, the

72 expression of four canonical pathways (i.e., Krebs cycle, synaptic long-term potentiation,  
73 steroid hormone metabolism and cAMP-mediated signaling) and the turnover of  
74 neurotransmitters, including dopamine and serotonin [11]. Importantly, microbiota  
75 reconstitution of GF mice in early life partially normalized their behavioral phenotypes,  
76 whereas colonization of adult GF mice had no effect. Together, these observations led to the  
77 concept of a sensitive period early in life, in which microbial colonization of the gut can  
78 influence brain development, function and behavior. Around the same time other groups  
79 independently published similar findings ([12, 13]; see online Milestone 18: The microbiota-  
80 gut-brain axis in Nature Milestones in Human Microbiota Research:  
81 <https://www.nature.com/immersive/d42859-019-00041-z/index.html>). Since then, several  
82 studies have demonstrated that the gut microbiota modulate a wide-range of  
83 neurodevelopmental processes, including blood-brain barrier (BBB) formation and integrity  
84 [14], microglial maturation and function [15, 16], and myelination [17-19], as well several  
85 complex behaviors (see Refs. [20, 21]). One important concept that has emerged from these  
86 preclinical studies is that certain influences of the gut microbiota on the brain are sex  
87 specific [22]. Other studies showed that gut bacteria influence behavioral abnormalities and  
88 associated brain pathology in animal models of neurodevelopmental and psychiatric  
89 disorders [23-25]. These preclinical and other clinical findings lent support to the hypothesis  
90 that gut microbiota may also influence the development of the human brain, and that its  
91 disruption could contribute to the pathogenesis of these disorders [25, 26].

92

93 It is now increasingly recognized that neurodevelopmental disorders such as autism  
94 spectrum disorder (ASD) are often co-morbid with gastrointestinal (GI) problems. For  
95 example, children with ASD have been reported to be six to eight times more likely to suffer  
96 from one or more chronic GI problems than typically developing children [27]. These GI  
97 issues include frequent abdominal pain, diarrhea, constipation, gaseousness, and painful  
98 stooling. Moreover, some studies have found a strong positive association of autism severity  
99 with GI dysfunction [28, 29]. These associations of ASD with increased prevalence of GI  
100 issues and reports of altered gut bacterial composition in this population motivate further  
101 explorations into the precise molecular mechanisms mediating the crosstalk between the  
102 gut microbiota and the developing brain [26, 30]. The gut microbiota contains trillions of  
103 bacteria which are source of a diverse peptidoglycome, bacterial peptidoglycan motifs that

104 are shed from the cell wall as bacteria divide [31, 32]. In this review, we highlight the  
105 emerging evidence supporting novel roles for bacterial peptidoglycans (PGN; a unique and  
106 essential component of the bacterial cell wall that is absent in eukaryotic cells) in  
107 neurodevelopment and behavior, after a general overview of key biological signaling  
108 pathways implicated in the microbiota-gut-brain axis. Finally, we discuss how alterations in  
109 the PGN signaling pathways early in life could impact neurodevelopmental trajectories and  
110 increase risk for neurodevelopmental disorders.

111

### 112 **Biological signaling pathways in the microbiota-gut-brain axis**

113 It has long been known that a complex bidirectional communication network exists between  
114 the gut and the central nervous system (CNS), referred to as the gut–brain axis. This network  
115 includes the sympathetic and parasympathetic branches of the autonomic nervous system,  
116 the enteric nervous system, neuroendocrine and neuroimmune pathways. In recent  
117 decades, the gut microbiota has been recognized as an important “third component” to the  
118 gut-brain axis, thus leading to the new concept of the microbiota-gut-brain axis. However,  
119 the precise molecular mechanisms mediating interactions between gut microbes and the  
120 brain have yet to be clearly defined. Emerging evidence suggests the involvement of multiple  
121 potential direct and indirect pathways (Figure 1), including signals carried by neuronal  
122 circuits (e.g., bidirectional vagus nerve-to-brain communication, and the enteric nervous  
123 system), activation of immune responses (e.g., cytokine and chemokine release within the  
124 gut or elsewhere that subsequently influence the brain), gut hormone signaling, tryptophan  
125 metabolism, and the production of microbial metabolites that indirectly or directly influence  
126 the brain, including bacterial fermentation metabolic by-products, such as short chain fatty  
127 acids (SCFAs; propionate, butyrate and acetate) (see Ref. [33]).

128

129 Undoubtedly, one of the most direct routes for the microbiota to communicate with the  
130 brain is through the vagus nerve [34]. Studies have shown that several probiotics (beneficial  
131 bacteria that produce health outcomes such as *Bifidobacterium* and *Lactobacillus* families,  
132 which do not possess pro-inflammatory lipopolysaccharide chains) utilize the vagus nerve  
133 signaling to communicate with the brain and influence behavior [35]. For example, the  
134 beneficial effects of *Lactobacillus (L.) rhamnosus* JB1 on stress-induced anxiety- and  
135 depression-related behavior are abolished by vagotomy [36]. Similarly, the vagus nerve is a

136 central gut-brain communication pathway by which *L. reuteri* MM4-1A rescue social deficits  
137 in several mouse models of ASD, including a genetic model (Shank3B mutant mice) [37],  
138 three environmental models (valproic acid, GF and maternal high-fat diet) [37, 38], and an  
139 idiopathic model (BTBR T+ Itpr3tf/J) of ASD [37]. However, the precise mechanisms by which  
140 *L. reuteri* interacts with the vagus nerve is not fully understood. It has recently been  
141 discovered that sensory cells from the GI tract with a primary endocrine function  
142 (enteroendocrine cells; referred to as neuropods) possess axon-like basal processes that  
143 form synapses with vagal afferents [39]. Therefore, it will be interesting to explore whether  
144 the actions of probiotics such as *L. reuteri* involve signaling through the neuropods. A recent  
145 optogenetic study showed that activation of gut-innervating vagal sensory ganglion neurons  
146 can also modulate reward-relating behavior (e.g., self-stimulation behavior and conditioned  
147 place preference) and dopamine release from the substantial nigra in mice, indicating that  
148 the vagal-gut-to brain axis is also an important component of the brain reward system [40].

149

150 In recent years, there has been a keen interest in the role of SCFAs since they exert many  
151 beneficial effects on host physiology (e.g., they enhance the integrity of the intestinal  
152 epithelial barrier and protect against inflammation) [41]. As SCFAs can interact with the gut–  
153 brain axis through several different mechanisms including the modulation of host chromatin  
154 structure and gene transcription as well as the activation of G-protein-couple receptors,  
155 exposure to these bacterial metabolites during critical time windows of development might  
156 have important implications for early-life programming of the brain and behavior. So far,  
157 there is evidence that acetate can cross the BBB at physiological levels [42], but it is unclear  
158 to what extent propionate and butyrate cross into the brain. Nevertheless, some studies  
159 have demonstrated that SCFA butyrate can restore the integrity of the BBB and that a mix of  
160 SCFAs can reverse aberrant microglia phenotypes in adult GF mice [14], indicating that SCFAs  
161 may be one of the signaling pathways by which bacteria modulate the brain. Several  
162 commensal bacteria have also been shown to produce neurotransmitters such as dopamine,  
163 serotonin, and metabolites that enter circulation and exert a range of consequences outside  
164 the GI tract [43]. With regard to the brain, a new study has shown that direct metabolites of  
165 the gut microbiome (e.g., imidazole propionate) or products of the combinatorial  
166 metabolism between the microbiome and host (e.g., 3-indoxyl-sulfate, trimethylamine-N-  
167 oxide, and phenylacetylglycine) are present in the forebrains of healthy mice as early as the

168 neonatal period and remain into adulthood [44]. However, the role of these metabolites in  
169 neurodevelopment remain poorly understood. Recently, studies have raised the possibility  
170 that bacterial-derived products such as PGN might directly affect the developing brain and  
171 behavior through central activation of pattern recognition receptors (PRRs) of the innate  
172 immune system [45].

173

### 174 **Pattern recognition receptors as potential key regulators of gut microbiota-brain** 175 **interactions**

176 There is growing recognition that PRRs have been adapted to mediate roles far beyond  
177 innate immunity, including host homeostasis and development [46]. PRRs are a series of  
178 germline-encoded host sensors that recognize highly conserved microbial molecular  
179 signatures or “motifs” such as bacterial surface molecules (e.g., PGN), often referred to as  
180 microbe- or pathogen-associated molecular patterns (MAMPs or PAMPs). Included among  
181 several important PRRs of the innate immune system are membrane-bound Toll-like  
182 receptors (TLRs; [47, 48]), cytosolic NOD-like receptors (nucleotide-binding domain leucine-  
183 rich repeat containing receptors; Nod1 and Nod2 receptors, [49, 50]) and PGN recognition  
184 proteins (PGRPs, Pglyrp1-4; [51, 52]). Traditionally, the expression and function of PRRs have  
185 been investigated in the context of pathogenic microorganisms. However, the microbial  
186 motifs that activate PRRs are not restricted to pathogens, since they include structural  
187 molecules such as lipopolysaccharide, a component of the outer membrane of Gram-  
188 negative bacteria, and PGN, common to almost all bacterial cell walls ([46]; [Figure 2](#)).

189

190 There is evidence from both invertebrates and vertebrates that motifs derived from  
191 commensal bacteria interact with PRRs to promote developmental processes and maintain  
192 homeostasis of the host [53]. For example, bacterial motifs have been implicated in the  
193 regression of a juvenile-specific epithelium that facilitates the colonization of the Hawaiian  
194 squid by the marine symbiotic bacterium *Vibrio fischeri*, which provides luminescence to the  
195 squid ([Figure 3A](#)) [54]. Moreover, the maturation of mammalian gut associated lymphoid  
196 tissues (i.e., isolated lymphoid follicles; ILFs) is triggered by the exposure of intestinal  
197 epithelial cells to PGN motifs derived from commensal Gram-negative bacteria during  
198 postnatal life, thus leading to the activation of the cytoplasmic PRR Nod1 and secretion of  
199 factors that stimulate the proliferation of isolated ILFs ([Figure 3B](#)) [7, 55] . Furthermore,



200 accumulating data indicate that PGN motifs from commensal bacteria can also diffuse  
201 through the epithelial barrier in the intestine and reach the systemic circulation. A seminal  
202 study by Clarke and colleagues showed that gut microbiota is a source of PGN that  
203 systemically primes the innate immune system [56]. Specifically, these authors showed  
204 translocation of the meso-diaminopimelic acid (meso-DAP)-type PGN from non-pathogenic  
205 Gram-negative bacteria from the intestinal mucosa to neutrophils in the bone marrow of  
206 mice. The activation of the cytoplasmic PRR Nod1 by meso-DAP-type PGN was sufficient to  
207 prime and restore neutrophil function in the bone marrow of mice with a manipulated  
208 microbiota (i.e., GF condition or antibiotic treated mice), thus revealing a previously  
209 undescribed role for PGN in priming systemic innate immunity in the absence of infection  
210 (Figure 3C). Other groups have recently detected traces of various PGN fragments in fetal  
211 bovine serum (the most widely used serum-supplement for *in vitro* cell culture) and serum of  
212 healthy mice [57], suggesting that a homeostatic function of PGN signaling may have been  
213 previously underappreciated.

214

215 A new antibody-based detection assay for the PGN muramyl-L-alanyl-D-isoglutamine (MDP)  
216 was described recently. The authors showed that this PGN monomer is ubiquitously present  
217 in serum or plasma of healthy humans, rodents and non-human primates [58]. It should be  
218 noted that a wide concentration range of MDP levels were found in healthy individuals from  
219 European or Asian ancestry. Approximately 75 % of all individuals had a range between 0.16-  
220 1 µg/ml, 22.5% between 1-4 ug/ml and at the extreme end of the spectrum either very high  
221 levels (4-5 ug/ml) or below the level of detection (see Figure 2d in Ref. [58]). However,  
222 patients suffering from autoimmune diseases (i.e., rheumatoid arthritis and systemic lupus  
223 erythematosus) had higher levels of circulating MDP than healthy controls, thus raising the  
224 possibility that disturbance of equilibria between PGN motifs and their sensing PRRs could  
225 contribute to host pathologic states. This finding is consistent with earlier work from Laman  
226 and colleagues showing the presence of antibodies specific for PGN in the cerebral spinal  
227 fluid (CSF) of patients with active multiple sclerosis (MS), and inflammatory demyelinating  
228 disease of the CNS [59]. For further details about the roles of PGN as driver of chronic brain  
229 inflammation in MS and its experimental autoimmune encephalomyelitis models, see a  
230 recent review by the latter authors [60].

231

232 **Bacterial PGN motifs can be translocated into the brain and sensed by innate immune**  
233 **PRRs**

234 The notion that bacterial products derived from microbiota could influence brain functions is  
235 not new [61, 62]. In fact, several decades ago, it was shown that some MDP-type PGN induce  
236 prolonged (6-12 h) increases in slow-wave sleep (SWS) in rabbits, rats and monkeys, and  
237 enhanced amplitude of EEG slow waves (0.5-4.0 Hz) during bouts of SWS. Of note, the  
238 somnogenic properties of muramyl peptides are dependent upon the precise biochemical  
239 structure (see Refs. [63, 64]), and can be distinguished from other activities of muramyl  
240 peptides such as induction of fever and adjuvant activity (see Ref. [61]). Moreover, PGN  
241 fragments were detected in the CSF and urine of patients with sleep disorders [65, 66], thus  
242 implicating PGN in the pathophysiology of sleep disorders. New scientific discoveries  
243 showing a previously unappreciated complexity of the human microbiome and its wide-  
244 ranging impact on host health and disease has triggered a re-evaluation of the possible role  
245 of microbial molecules and metabolites on host tissues, including the brain. Recently,  
246 Arentsen and colleagues showed the presence of PGN fragments in the serum of healthy  
247 juvenile mice (*i.e.*, specific-pathogen-free mice; see also Figure 2e in Ref. [58]). PGN levels in  
248 the serum of juvenile GF mice were found to be very low or at the limits of detection,  
249 confirming that microbiota is the main source of PGN in the circulation. The same authors  
250 showed the presence of PGN fragments in the normal developing mouse brain, which  
251 increases in parallel with the postnatal bacterial colonization processes ([45]; [Figure 4A](#)). It  
252 was also demonstrated that two families of PRRs that specifically detect PGN [*i.e.*, PGN-  
253 recognition proteins (PGRPs) and NOD-like receptors] and the PGN transporter PepT1 are  
254 highly expressed in the developing brain during distinct windows of postnatal mouse  
255 development. These findings raise the possibility that PGN motifs (for example, muramyl  
256 dipeptides and mesoDAP-type PGN) may differentially affect brain development depending  
257 upon the postnatal age. At least two PGN-sensing molecules (Pglyrp2 and Nod1) have been  
258 found to be highly expressed in neurons in several brain regions including the prefrontal  
259 cortex, hippocampus and cerebellum, thus indicating potential direct effects of PGN on  
260 neurons ([45]; [Figure 4B](#)). Interestingly, the peak expression of Nod1 receptors coincides  
261 with the period of synaptogenesis in rodents. These molecules are also expressed in  
262 astrocytes and microglia (albeit at lower levels than in neurons). In addition, oligodendrocyte  
263 development and maturation may be affected by PGN since they express some PGN-sensing

264 molecules such as Nod1, according to an open access database containing transcriptomic  
265 datasets from oligodendrocytes from different developmental stages  
266 (<https://ki.se/en/mbb/oligointernode>). It is worthwhile pointing out that the expression of  
267 PGN-sensing molecules (PGRP1-4, Nod1, Nod2, Tlr2, PepT1) is highly sensitive to  
268 manipulations of the gut microbiota (*i.e.*, GF condition and perinatal antibiotic exposure)  
269 within the developing brain [45]. Moreover, there are brain region-dependent and sex-  
270 dependent differences in the expression of PGN-sensing molecules during postnatal brain  
271 development. Interestingly, these differences appear to be more pronounced in the  
272 prefrontal cortex, a key region implicated on a broad range of neurodevelopmental and  
273 psychiatric disorders [67]. Taken together, these findings suggest that a highly dynamic and  
274 sensitive period exists, during which postnatal microbial gut colonization can influence  
275 developmental brain trajectories in an age-, region- and sex-specific manner via PGN  
276 signaling.

277

### 278 **Emerging roles of PGN-sensing molecules on brain development, function and behavior**

279 There is a growing body of literature demonstrating that classical peripheral immune  
280 molecules can have important roles in the CNS under normal physiological conditions. For  
281 instance, the major histocompatibility complex (MHC) class I and the paired-  
282 immunoglobulin-like receptor B (PirB; an MHCI-binding receptor) have been implicated in  
283 synaptic plasticity, learning and memory [68-70]. Moreover, some members of the TLR  
284 family have been shown to modulate key neurodevelopmental processes (e.g., neurite  
285 outgrowth, neuronal proliferation/differentiation, and neuronal cell death) and behavior  
286 [71-77]. Emerging evidence also points to novel roles for PGN-sensing molecules (that is  
287 PGRPs and NOD-like receptors) in the CNS [78]. The first known function of a PGN-sensing  
288 molecule in the CNS came from the *Drosophila* model system [79]. The authors  
289 demonstrated that a member of the PGRP family (PGRP-LC) is expressed at the presynaptic  
290 terminal of *Drosophila* motor neurons. This PGN-sensing molecule plays a key role in the  
291 induction and sustained expression of presynaptic homeostatic plasticity; thus, it controls  
292 the homeostatic modulation of the readily releasable pool of synaptic vesicles following  
293 inhibition of postsynaptic glutamate receptor function.

294

295 In mammals, there are four PGRPs including a “long” isoform (Pglyrp2 or PGRP-L) that is a N-  
296 acetylmuramoyl-l-alanine amidase that hydrolyzes the amide bond between MurNAc and l-  
297 Ala of bacterial PGN (which is unique among the mammalian PGRPs) [52]. In mice, Pglyrp2 is  
298 highly expressed in the brain (e.g., prefrontal cortex, striatum, hippocampus and cerebellum)  
299 during the first few days of life [45]. In line with this, human PGLYRP2 protein has also been  
300 detected in postmortem cerebral cortex tissue of a young child, but not in most adult  
301 cortical tissues [i.e., moderate to strong labelling in the neuropil and glial cells, respectively;  
302 the Human Protein Atlas; (<https://www.proteinatlas.org/>) [80]]. In a recent study, it was  
303 demonstrated that Pglyrp2 knockout (KO) mice have an altered expression of the ASD risk  
304 gene c-Met, and BDNF (brain-derived neurotrophic factor) [45], both implicated in the  
305 formation and modulation of brain circuits [81, 82]. Moreover, juvenile Pglyrp2 KO mice  
306 display a significant increase in social interaction levels toward an unfamiliar stimuli mouse,  
307 without any alterations in anxiety-like behavior or motor activity [45]. Interestingly, this  
308 phenotype was more pronounced in male offspring. In another study, the same authors  
309 demonstrated that the absence of Pglyrp2 leads to major sex-dependent alterations in  
310 motor and anxiety-like behavior later in adulthood (i.e., 15 month-old mice) [83]. In this  
311 case, Pglyrp2-deficient female mice, but not males, show better motor performance.  
312 However, they display increased levels of anxiety-like behavior, suggesting that the  
313 modulatory effects of Pglyrp2 in the brain are highly dependent upon multiple host factors  
314 including age, sex and type of neuronal circuits. Peptidoglycan recognition protein 1  
315 (Pglyrp1, also known as tag7 protein or PGRP-S) is another member of the mammalian PGRP  
316 family that is expressed in the brain. Unlike Pglyrp2, the expression of Pglyrp1 peaks around  
317 the second week of postnatal life and continues to be expressed into adulthood [45].  
318 Previous work has shown that PGRP1 mRNA levels increase in brain stem and hypothalamus  
319 after sleep deprivation in rodents [84], suggesting a possible role for this PGN-sensing  
320 molecule in homeostatic regulation of sleep. However, studies using more advanced  
321 transgenic mouse models (e.g., conditional brain-specific knockdown of Pglyrp2) are  
322 fundamental to unravel the specific role of PGRPs in the CNS.

323

324 Recently, Pusceddu and colleagues provided the first experimental evidence implicating the  
325 NOD-like receptors in the regulation of the stress response, serotonin (5-HT) signaling and  
326 behavior [85]. Specifically, these authors showed that NodDKO mice deficient in both Nod1

327 and Nod2 exhibit signs of stress-induced anxiety-like behavior, cognitive impairment and  
328 depressive-like behavior under conditions of a hyperactive HPA axis, but not under baseline  
329 conditions. Surprisingly, no major sex differences were found. Moreover, these authors  
330 identified the central 5-HT system as one potential neural substrate mediating the  
331 behavioral phenotype of NodDKO mice. In fact, NodDKO mice had lower levels of 5-HT in  
332 both the hippocampus and brain stem under basal conditions. In addition, the expression  
333 profile of several key components of the 5-HT signaling pathways such as tryptophan  
334 hydroxylase 2 (the rate limiting enzyme for 5-HT synthesis), the 5-HT receptor 1a (which  
335 regulates 5-HT release) and the 5-HT transporter were impaired after exposure to stress.  
336 Importantly, these authors showed that the stress-induced behavioral impairments  
337 observed in NodDKO mice could be restored by chronic treatment with a 5-HT reuptake  
338 inhibitor (fluoxetine). Another important finding of this study was that intestinal epithelial  
339 cell (IEC)-specific ablation of Nod1 (VilCre+Nod1f/f), but not Nod2 receptors, resulted in  
340 stress-induced impairments in cognitive function and anxiety-like behavior. The latter  
341 observations highlight a novel role for the IEC Nod1 receptors in behavioral responses to  
342 stress and identify this PGN-sensing molecule as potential new target for the treatment of  
343 stress-associated gut-brain disorders. However, the specific roles of NOD-like receptors  
344 within the brain remain to be further clarified. Previous studies have shown that murine  
345 microglia express robust levels of Nod2 mRNA and protein, but little or no expression of  
346 Nod1 [86, 87]. On the other hand, Nod1 protein is highly expressed in developing neurons  
347 across multiple brain regions including the prefrontal cortex, hippocampus and cerebellum  
348 (see supplementary figure 3 in Ref. [45]). Both Nod1 and Nod2 are moderately expressed in  
349 astrocytes [45, 87]. These findings raise the possibility that Nod1 and Nod2 may have distinct  
350 functions in glia and neurons of the adult and developing brain.

351

### 352 **Potential role of PGN in the Pathophysiology of Neurodevelopmental Disorders**

353 It is now widely recognized that the maternal-fetal environment plays a crucial role in the  
354 development of the fetal brain and long-term neurodevelopmental trajectories, including  
355 susceptibility to mental health disorders in childhood and adulthood [88]. Indeed,  
356 epidemiological studies have shown an association between maternal infection/  
357 inflammation during pregnancy and increased risk for neurodevelopmental and psychiatric  
358 disorders such as ASD [89-92]. These findings are supported by experimental mouse studies

359 demonstrating that maternal immune activation during pregnancy (MIA; through exposure  
360 to microbial pathogens or pro-inflammatory PAMPs) induces ASD-like behavioral traits in  
361 their offspring [93, 94]. Recent work by Choi, Huh and colleagues have demonstrated that  
362 MIA promotes abnormal cortical development and ASD-like behavioral phenotypes in mouse  
363 offspring through the activation of the maternal T helper 17 cell-interleukin-17a (IL-17a)  
364 pathway [95]. These authors discovered that MIA-induced phenotypes in mouse offspring  
365 require commensal maternal gut bacteria (*i.e.*, segmented filamentous bacteria; SFB) that  
366 promote Th17 cell differentiation [96]. For instance, pregnant C57BL/6 mice, which are  
367 colonized with SFB and contain higher numbers of gut Th17 cells were more susceptible to  
368 MIA-induced behavioral and morphological pathology. Conversely, pregnant C57BL/6 mice  
369 which are not colonized by SFB and lack gut Th17 cells were not susceptible. These findings  
370 suggest that the composition of the maternal gut microbiota is an important contributing  
371 risk factor for MIA-induced behavioral abnormalities in offspring. Indeed, mounting evidence  
372 identifies the maternal gut microbiota as a common denominator by which a broad range of  
373 environmental risk factors such as diet (e.g., high-fat diet), infections, antibiotic exposure  
374 and stress can affect both the maternal health and fetal development [9, 97, 98]. The  
375 developing fetus receives oxygen and nutrients along other bioactive compounds from the  
376 maternal circulation, and therefore, alterations in the composition and metabolic activity of  
377 maternal gut microbiota could profoundly influence prenatal brain development processes  
378 (e.g., neurogenesis, migration, and differentiation) and subsequent neurodevelopmental  
379 outcomes. In line with this notion, a new study in mice demonstrated that during normal  
380 pregnancy, SCFAs from the commensal maternal gut microbiota can reach the developing  
381 embryo and promote the differentiation of sympathetic neurons via activation of GPR41  
382 [99]. Moreover, studies demonstrating disrupted BBB maturation and an altered microglial  
383 transcriptome profile in GF mice during prenatal life underscores the importance of the  
384 commensal maternal microbiome during fetal brain development [14, 16].

385

386 Recently, it has been proposed that MAMPs such as PGN could be an important mediator of  
387 host-microbiome interactions at the maternal-fetal interface since PGN reaches the systemic  
388 circulation not only during bacterial infections, but also during normal physiological  
389 conditions [78]. In line with this notion, a recent study showed that components of the  
390 bacterial cell wall (*i.e.*, PGN-teichoic acid complex of *Streptococcus pneumoniae*, a major

391 pathogen causing infections such as meningitis) can traverse the placental barrier through  
392 the platelet activating factor receptor (PAFr) and affect the developing mouse fetal brain  
393 [100]. This PGN-teichoic acid complex induces the transcription factor FoxG1 in the fetal  
394 neocortex via the activation of the Tlr2, resulting in a 50% greater density of neurons in the  
395 cortical plate. This abnormal neuroproliferation was associated with abnormal cognitive  
396 development. Intriguingly, a Tlr-2-dependent response to this PAM did not induce  
397 inflammation in the fetal brain. Recently, it was reported that NOD1, NOD2, TLR2, as well as  
398 the putative PGN transporters PEPT2 and PAFr are abundantly expressed in the human  
399 placenta [78]. These findings suggest that bacterial PGN motifs from the maternal  
400 commensal gut microbiota may also be capable of influencing the developing brain, and that  
401 disruption of components of this signaling pathway could lead to abnormal motor, social,  
402 and cognitive development (Figure 5).

403

404 In humans, accelerated brain growth in infancy has been associated with a broad range of  
405 developmental delays in motor, language, and cognitive functions [101, 102]. For instance,  
406 neurodevelopmental disorders, including ASD, have been associated with atypical brain  
407 connectivity patterns involving higher-order association neocortical regions [103-105]. A  
408 large proportion of high-confidence ASD-associated risk genes are pleiotropic, and affect  
409 proliferation/differentiation and/or synapse development in the neocortex, amygdala,  
410 hippocampus, striatum and cerebellum, supporting the notion that ASD begins during  
411 prenatal life [106]. It will therefore be of great interest to investigate the potential link  
412 between maternal circulating PGN levels during pregnancy, and social-cognitive  
413 development of infants, as well as potential novel associations between genetic variants in  
414 PGN-sensing molecules and ASD ([107]; see Clinician's Corner).

415

### 416 **Concluding Remarks**

417 Recent discoveries showing an unprecedented role for the commensal gut microbiota in the  
418 regulation of brain development and behavior has triggered a paradigm shift in our  
419 conceptualization of the origin of human brain disorders. The current focus of this new  
420 microbiome-gut-brain axis field is to delineate the precise molecular mechanisms and  
421 signaling pathways employed by commensal gut bacteria to influence the brain. PRRs that  
422 recognize bacterial surface molecules, such as PGN, have emerged as potential novel

423 mediators of microbiota-gut–brain axis signaling. The gut microbiota contains trillions of  
424 commensal bacteria producing a diverse peptidoglycome that can disseminate systemically  
425 and reach peripheral organs such as the brain. PRRs that specifically recognize PGN (i.e.,  
426 PGN-sensing molecules; NOD-like receptors and PGN-recognition proteins), and the PGN  
427 transporter PepT1 are highly expressed in the developing brain during specific windows of  
428 postnatal development. Emerging evidence suggests crucial roles for PGN-sensing molecules  
429 in the regulation of social behavior and anxiety, and behavioral responses to stress. Despite  
430 recent advances, many questions remain to be answered, including the characterization of  
431 the specific types of PGN that can cross the BBB under physiological conditions, and how  
432 they are transported into brain cells (neurons, astrocytes, microglia and oligodendrocytes  
433 (see [Outstanding Questions](#)). It is worthwhile acknowledging that the laboratory of  
434 Gomperts Boneca at the Institut Pasteur in Paris has been advancing some of these  
435 questions by combining different PGN labelling methods with advanced imaging and genetic  
436 approaches (see abstracts from the Great Wall Symposium 2019, September 25-27, 2019).  
437 From a clinical perspective, it would be of great importance to determine whether serum or  
438 plasma levels of PGN motifs during pregnancy and/ or early postnatal life could help to  
439 identify infants and children at risk for atypical social and cognitive development. It would be  
440 equally important to identify potential genetic risk variants involved in the sensing of  
441 bacterial-derived products (e.g., by creating a polygene risk scores of key genes involved in  
442 PGN-sensing molecules) that are associated with atypical neurodevelopmental trajectories.  
443 This could be accomplished in a multicenter, prospective, longitudinal study of infants at  
444 high- and low-risk for atypical brain development such as ASD. In parallel, investigate  
445 potential effects of PGN motifs on early aspects of human brain prenatal development by  
446 taking advantage of human induced pluripotent stem cells technology, which allows the  
447 generation of personalized neurons or glial cells. This information will provide key  
448 mechanistic insight into how PGN can influence brain development, function and behavior,  
449 as well as novel potential therapeutic targets for the treatment of neurodevelopmental and  
450 psychiatric disorders, often associated with co-morbid gastrointestinal problems and altered  
451 gut microbiota composition.

452

453 **Acknowledgments**



454 The authors apologize to colleagues whose publications were not cited due to space  
455 constraints and the special focus on recent work. Work from the Diaz Heijtz laboratory cited  
456 in this review has been supported by grants from the Swedish Research Council, Swedish  
457 Brain Foundation, Olle Engkvist Byggmästare Foundation and the Frimurare Barnhus  
458 Foundation. All figures were partially created using BioRender (<https://biorender.com>).

459

## 460 **References**

- 461 1. Dominguez-Bello, M.G. et al. (2019) Role of the microbiome in human development. *Gut* 68 (6),  
462 1108-1114.
- 463 2. Sender, R. et al. (2016) Are We Really Vastly Outnumbered? Revisiting the Ratio of Bacterial to  
464 Host Cells in Humans. *Cell* 164 (3), 337-40.
- 465 3. Tierney, B.T. et al. (2019) The Landscape of Genetic Content in the Gut and Oral Human  
466 Microbiome. *Cell Host Microbe* 26 (2), 283-295 e8.
- 467 4. Qin, J. et al. (2010) A human gut microbial gene catalogue established by metagenomic  
468 sequencing. *Nature* 464 (7285), 59-65.
- 469 5. Cho, I. and Blaser, M.J. (2012) The human microbiome: at the interface of health and disease. *Nat*  
470 *Rev Genet* 13 (4), 260-70.
- 471 6. Rowland, I. et al. (2018) Gut microbiota functions: metabolism of nutrients and other food  
472 components. *Eur J Nutr* 57 (1), 1-24.
- 473 7. Al Nabhani, Z. and Eberl, G. (2020) Imprinting of the immune system by the microbiota early in life.  
474 *Mucosal Immunol* 13 (2), 183-189.
- 475 8. Borre, Y.E. et al. (2014) Microbiota and neurodevelopmental windows: implications for brain  
476 disorders. *Trends Mol Med* 20 (9), 509-18.
- 477 9. Diaz Heijtz, R. (2016) Fetal, neonatal, and infant microbiome: Perturbations and subsequent effects  
478 on brain development and behavior. *Semin Fetal Neonatal Med* 21 (6), 410-417.
- 479 10. Sudo, N. et al. (2004) Postnatal microbial colonization programs the hypothalamic-pituitary-  
480 adrenal system for stress response in mice. *J Physiol* 558 (Pt 1), 263-75.
- 481 11. Diaz Heijtz, R. et al. (2011) Normal gut microbiota modulates brain development and behavior.  
482 *Proc Natl Acad Sci U S A* 108 (7), 3047-52.
- 483 12. Neufeld, K.M. et al. (2011) Reduced anxiety-like behavior and central neurochemical change in  
484 germ-free mice. *Neurogastroenterol Motil* 23 (3), 255-64, e119.
- 485 13. Clarke, G. et al. (2013) The microbiome-gut-brain axis during early life regulates the hippocampal  
486 serotonergic system in a sex-dependent manner. *Mol Psychiatry* 18 (6), 666-73.
- 487 14. Braniste, V. et al. (2014) The gut microbiota influences blood-brain barrier permeability in mice.  
488 *Sci Transl Med* 6 (263), 263ra158.
- 489 15. Erny, D. et al. (2015) Host microbiota constantly control maturation and function of microglia in  
490 the CNS. *Nat Neurosci* 18 (7), 965-77.
- 491 16. Thion, M.S. et al. (2018) Microbiome Influences Prenatal and Adult Microglia in a Sex-Specific  
492 Manner. *Cell* 172 (3), 500-516 e16.
- 493 17. Gacias, M. et al. (2016) Microbiota-driven transcriptional changes in prefrontal cortex override  
494 genetic differences in social behavior. *Elife* 5, e13442.
- 495 18. Hoban, A.E. et al. (2016) Regulation of prefrontal cortex myelination by the microbiota. *Transl*  
496 *Psychiatry* 6, e774.
- 497 19. Radulescu, C.I. et al. (2019) Manipulation of microbiota reveals altered callosal myelination and  
498 white matter plasticity in a model of Huntington disease. *Neurobiol Dis* 127, 65-75.
- 499 20. Lynch, J.B. and Hsiao, E.Y. (2019) Microbiomes as sources of emergent host phenotypes. *Science*  
500 365 (6460), 1405-1409.

- 501 21. Sherwin, E. et al. (2019) Microbiota and the social brain. *Science* 366 (6465).
- 502 22. Jaggar, M. et al. (2020) You've got male: Sex and the microbiota-gut-brain axis across the lifespan.
- 503 *Front Neuroendocrinol* 56, 100815.
- 504 23. Needham, B.D. et al. (2018) Searching for the gut microbial contributing factors to social behavior
- 505 in rodent models of autism spectrum disorder. *Dev Neurobiol* 78 (5), 474-499.
- 506 24. Hsiao, E.Y. et al. (2013) Microbiota modulate behavioral and physiological abnormalities
- 507 associated with neurodevelopmental disorders. *Cell* 155 (7), 1451-63.
- 508 25. Lum, G.R. et al. (2020) Emerging roles for the intestinal microbiome in epilepsy. *Neurobiol Dis*
- 509 135, 104576.
- 510 26. Vuong, H.E. and Hsiao, E.Y. (2017) Emerging Roles for the Gut Microbiome in Autism Spectrum
- 511 Disorder. *Biol Psychiatry* 81 (5), 411-423.
- 512 27. Chaidez, V. et al. (2014) Gastrointestinal problems in children with autism, developmental delays
- 513 or typical development. *J Autism Dev Disord* 44 (5), 1117-27.
- 514 28. Adams, J.B. et al. (2011) Gastrointestinal flora and gastrointestinal status in children with autism--
- 515 comparisons to typical children and correlation with autism severity. *BMC Gastroenterol* 11, 22.
- 516 29. Wang, L.W. et al. (2011) The prevalence of gastrointestinal problems in children across the United
- 517 States with autism spectrum disorders from families with multiple affected members. *J Dev Behav*
- 518 *Pediatr* 32 (5), 351-60.
- 519 30. Srikantha, P. and Mohajeri, M.H. (2019) The Possible Role of the Microbiota-Gut-Brain-Axis in
- 520 Autism Spectrum Disorder. *Int J Mol Sci* 20 (9).
- 521 31. Wheeler, R. et al. (2014) The biology of bacterial peptidoglycans and their impact on host
- 522 immunity and physiology. *Cell Microbiol* 16 (7), 1014-23.
- 523 32. Irazoki, O. et al. (2019) Peptidoglycan Muropeptides: Release, Perception, and Functions as
- 524 Signaling Molecules. *Front Microbiol* 10, 500.
- 525 33. Cryan, J.F. et al. (2019) The Microbiota-Gut-Brain Axis. *Physiol Rev* 99 (4), 1877-2013.
- 526 34. Fulling, C. et al. (2019) Gut Microbe to Brain Signaling: What Happens in Vagus. *Neuron* 101 (6),
- 527 998-1002.
- 528 35. Sarkar, A. et al. (2018) The Microbiome in Psychology and Cognitive Neuroscience. *Trends Cogn*
- 529 *Sci* 22 (7), 611-636.
- 530 36. Sarkar, A. et al. (2016) Psychobiotics and the Manipulation of Bacteria-Gut-Brain Signals. *Trends*
- 531 *Neurosci* 39 (11), 763-781.
- 532 37. Sgritta, M. et al. (2019) Mechanisms Underlying Microbial-Mediated Changes in Social Behavior in
- 533 Mouse Models of Autism Spectrum Disorder. *Neuron* 101 (2), 246-259 e6.
- 534 38. Buffington, S.A. et al. (2016) Microbial Reconstitution Reverses Maternal Diet-Induced Social and
- 535 Synaptic Deficits in Offspring. *Cell* 165 (7), 1762-1775.
- 536 39. Kaelberer, M.M. et al. (2018) A gut-brain neural circuit for nutrient sensory transduction. *Science*
- 537 361 (6408).
- 538 40. Han, W. et al. (2018) A Neural Circuit for Gut-Induced Reward. *Cell* 175 (3), 665-678 e23.
- 539 41. Silva, Y.P. et al. (2020) The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain
- 540 Communication. *Front Endocrinol (Lausanne)* 11, 25.
- 541 42. Frost, G. et al. (2014) The short-chain fatty acid acetate reduces appetite via a central
- 542 homeostatic mechanism. *Nat Commun* 5, 3611.
- 543 43. Caspani, G. and Swann, J. (2019) Small talk: microbial metabolites involved in the signaling from
- 544 microbiota to brain. *Curr Opin Pharmacol* 48, 99-106.
- 545 44. Swann, J.R. et al. (2020) Developmental Signatures of Microbiota-Derived Metabolites in the
- 546 Mouse Brain. *Metabolites* 10 (5).
- 547 45. Arentsen, T. et al. (2017) The bacterial peptidoglycan-sensing molecule Pglyrp2 modulates brain
- 548 development and behavior. *Mol Psychiatry* 22 (2), 257-266.
- 549 46. Chu, H. and Mazmanian, S.K. (2013) Innate immune recognition of the microbiota promotes host-
- 550 microbial symbiosis. *Nat Immunol* 14 (7), 668-75.
- 551 47. Beutler, B. (2004) Inferences, questions and possibilities in Toll-like receptor signalling. *Nature*
- 552 430 (6996), 257-63.

- 553 48. Moresco, E.M. et al. (2011) Toll-like receptors. *Curr Biol* 21 (13), R488-93.
- 554 49. Philpott, D.J. et al. (2014) NOD proteins: regulators of inflammation in health and disease. *Nat*
- 555 *Rev Immunol* 14 (1), 9-23.
- 556 50. Mukherjee, T. et al. (2019) NOD1 and NOD2 in inflammation, immunity and disease. *Arch*
- 557 *Biochem Biophys* 670, 69-81.
- 558 51. Royet, J. and Dziarski, R. (2007) Peptidoglycan recognition proteins: pleiotropic sensors and
- 559 effectors of antimicrobial defences. *Nat Rev Microbiol* 5 (4), 264-77.
- 560 52. Royet, J. et al. (2011) Peptidoglycan recognition proteins: modulators of the microbiome and
- 561 inflammation. *Nat Rev Immunol* 11 (12), 837-51.
- 562 53. McFall-Ngai, M. et al. (2013) Animals in a bacterial world, a new imperative for the life sciences.
- 563 *Proc Natl Acad Sci U S A* 110 (9), 3229-36.
- 564 54. McFall-Ngai, M. et al. (2010) The role of the immune system in the initiation and persistence of
- 565 the *Euprymna scolopes*-*Vibrio fischeri* symbiosis. *Semin Immunol* 22 (1), 48-53.
- 566 55. Bouskra, D. et al. (2008) Lymphoid tissue genesis induced by commensals through NOD1
- 567 regulates intestinal homeostasis. *Nature* 456 (7221), 507-10.
- 568 56. Clarke, T.B. et al. (2010) Recognition of peptidoglycan from the microbiota by Nod1 enhances
- 569 systemic innate immunity. *Nat Med* 16 (2), 228-31.
- 570 57. Molinaro, R. et al. (2019) Trace levels of peptidoglycan in serum underlie the NOD-dependent
- 571 cytokine response to endoplasmic reticulum stress. *J Biol Chem* 294 (22), 9007-9015.
- 572 58. Huang, Z. et al. (2019) Antibody neutralization of microbiota-derived circulating peptidoglycan
- 573 dampens inflammation and ameliorates autoimmunity. *Nat Microbiol* 4 (5), 766-773.
- 574 59. Schrijver, I.A. et al. (2001) Bacterial peptidoglycan and immune reactivity in the central nervous
- 575 system in multiple sclerosis. *Brain* 124 (Pt 8), 1544-54.
- 576 60. Laman, J.D. et al. (2020) Bacterial peptidoglycan as a driver of chronic brain inflammation. *Trends*
- 577 *Mol Med*, In Press.
- 578 61. Krueger, J.M. and Opp, M.R. (2016) Sleep and Microbes. *Int Rev Neurobiol* 131, 207-225.
- 579 62. Kubota, K. (1989) Kuniomi Ishimori and the first discovery of sleep-inducing substances in the
- 580 brain. *Neurosci Res* 6 (6), 497-518.
- 581 63. Johannsen, L. et al. (1994) Somnogenic activity of muramyl peptide-derived immune adjuvants.
- 582 *Int J Immunopharmacol* 16 (2), 109-16.
- 583 64. Johannsen, L. et al. (1989) Somnogenic activity of O-acetylated and dimeric muramyl peptides.
- 584 *Infect Immun* 57 (9), 2726-32.
- 585 65. Krueger, J.M. et al. (1982) The composition of sleep-promoting factor isolated from human urine.
- 586 *J Biol Chem* 257 (4), 1664-9.
- 587 66. Martin, S.A. et al. (1984) Peptidoglycans as promoters of slow-wave sleep. I. Structure of the
- 588 sleep-promoting factor isolated from human urine. *J Biol Chem* 259 (20), 12652-8.
- 589 67. Bicks, L.K. et al. (2015) Prefrontal Cortex and Social Cognition in Mouse and Man. *Front Psychol* 6,
- 590 1805.
- 591 68. Boulanger, L.M. and Shatz, C.J. (2004) Immune signalling in neural development, synaptic
- 592 plasticity and disease. *Nat Rev Neurosci* 5 (7), 521-31.
- 593 69. Djuricic, M. et al. (2013) PirB regulates a structural substrate for cortical plasticity. *Proc Natl Acad*
- 594 *Sci U S A* 110 (51), 20771-6.
- 595 70. Lee, H. et al. (2014) Synapse elimination and learning rules co-regulated by MHC class I H2-Db.
- 596 *Nature* 509 (7499), 195-200.
- 597 71. Lathia, J.D. et al. (2008) Toll-like receptor 3 is a negative regulator of embryonic neural progenitor
- 598 cell proliferation. *J Neurosci* 28 (51), 13978-84.
- 599 72. Ma, Y. et al. (2006) Toll-like receptor 8 functions as a negative regulator of neurite outgrowth and
- 600 inducer of neuronal apoptosis. *J Cell Biol* 175 (2), 209-15.
- 601 73. Okun, E. et al. (2011) Toll-like receptor signaling in neural plasticity and disease. *Trends Neurosci*
- 602 34 (5), 269-81.
- 603 74. Okun, E. et al. (2010) TLR2 activation inhibits embryonic neural progenitor cell proliferation. *J*
- 604 *Neurochem* 114 (2), 462-74.

- 605 75. Shechter, R. et al. (2008) Toll-like receptor 4 restricts retinal progenitor cell proliferation. *J Cell*  
606 *Biol* 183 (3), 393-400.
- 607 76. Okun, E. et al. (2012) Evidence for a developmental role for TLR4 in learning and memory. *PLoS*  
608 *One* 7 (10), e47522.
- 609 77. Okun, E. et al. (2010) Toll-like receptor 3 inhibits memory retention and constrains adult  
610 hippocampal neurogenesis. *Proc Natl Acad Sci U S A* 107 (35), 15625-30.
- 611 78. Tosoni, G. et al. (2019) Bacterial peptidoglycans as novel signaling molecules from microbiota to  
612 brain. *Curr Opin Pharmacol* 48, 107-113.
- 613 79. Harris, N. et al. (2015) The Innate Immune Receptor PGRP-LC Controls Presynaptic Homeostatic  
614 Plasticity. *Neuron* 88 (6), 1157-1164.
- 615 80. Thul, P.J. et al. (2017) A subcellular map of the human proteome. *Science* 356 (6340).
- 616 81. Eagleson, K.L. et al. (2017) The Pleiotropic MET Receptor Network: Circuit Development and the  
617 Neural-Medical Interface of Autism. *Biol Psychiatry* 81 (5), 424-433.
- 618 82. Park, H. and Poo, M.M. (2013) Neurotrophin regulation of neural circuit development and  
619 function. *Nat Rev Neurosci* 14 (1), 7-23.
- 620 83. Arentsen, T. et al. (2018) Sex-dependent alterations in motor and anxiety-like behavior of aged  
621 bacterial peptidoglycan sensing molecule 2 knockout mice. *Brain Behav Immun* 67, 345-354.
- 622 84. Rehman, A. et al. (2001) The cloning of a rat peptidoglycan recognition protein (PGRP) and its  
623 induction in brain by sleep deprivation. *Cytokine* 13 (1), 8-17.
- 624 85. Pusceddu, M.M. et al. (2019) Nod-like receptors are critical for gut-brain axis signalling in mice. *J*  
625 *Physiol* 597 (24), 5777-5797.
- 626 86. Sterka, D., Jr. and Marriott, I. (2006) Characterization of nucleotide-binding oligomerization  
627 domain (NOD) protein expression in primary murine microglia. *J Neuroimmunol* 179 (1-2), 65-75.
- 628 87. Sterka, D., Jr. et al. (2006) Functional expression of NOD2, a novel pattern recognition receptor  
629 for bacterial motifs, in primary murine astrocytes. *Glia* 53 (3), 322-30.
- 630 88. Al-Haddad, B.J.S. et al. (2019) The fetal origins of mental illness. *Am J Obstet Gynecol* 221 (6),  
631 549-562.
- 632 89. Lee, B.K. et al. (2015) Maternal hospitalization with infection during pregnancy and risk of autism  
633 spectrum disorders. *Brain Behav Immun* 44, 100-5.
- 634 90. Atladottir, H.O. et al. (2010) Maternal infection requiring hospitalization during pregnancy and  
635 autism spectrum disorders. *J Autism Dev Disord* 40 (12), 1423-30.
- 636 91. Bokobza, C. et al. (2019) Neuroinflammation in preterm babies and autism spectrum disorders.  
637 *Pediatr Res* 85 (2), 155-165.
- 638 92. Patterson, P.H. (2011) Maternal infection and immune involvement in autism. *Trends Mol Med*  
639 17 (7), 389-94.
- 640 93. Brown, A.S. and Meyer, U. (2018) Maternal Immune Activation and Neuropsychiatric Illness: A  
641 Translational Research Perspective. *Am J Psychiatry* 175 (11), 1073-1083.
- 642 94. Estes, M.L. and McAllister, A.K. (2016) Maternal immune activation: Implications for  
643 neuropsychiatric disorders. *Science* 353 (6301), 772-7.
- 644 95. Reed, M.D. et al. (2020) IL-17a promotes sociability in mouse models of neurodevelopmental  
645 disorders. *Nature* 577 (7789), 249-253.
- 646 96. Kim, S. et al. (2017) Maternal gut bacteria promote neurodevelopmental abnormalities in mouse  
647 offspring. *Nature* 549 (7673), 528-532.
- 648 97. Codagnone, M.G. et al. (2019) Programming Bugs: Microbiota and the Developmental Origins of  
649 Brain Health and Disease. *Biol Psychiatry* 85 (2), 150-163.
- 650 98. Jasarevic, E. and Bale, T.L. (2019) Prenatal and postnatal contributions of the maternal  
651 microbiome on offspring programming. *Front Neuroendocrinol* 55, 100797.
- 652 99. Kimura, I. et al. (2020) Maternal gut microbiota in pregnancy influences offspring metabolic  
653 phenotype in mice. *Science* 367 (6481).
- 654 100. Humann, J. et al. (2016) Bacterial Peptidoglycan Traverses the Placenta to Induce Fetal  
655 Neuroproliferation and Aberrant Postnatal Behavior. *Cell Host Microbe* 19 (3), 388-99.

- 656 101. Courchesne, E. et al. (2001) Unusual brain growth patterns in early life in patients with autistic  
657 disorder: an MRI study. *Neurology* 57 (2), 245-54.
- 658 102. Hazlett, H.C. et al. (2005) Magnetic resonance imaging and head circumference study of brain  
659 size in autism: birth through age 2 years. *Arch Gen Psychiatry* 62 (12), 1366-76.
- 660 103. Hahamy, A. et al. (2015) The idiosyncratic brain: distortion of spontaneous connectivity patterns  
661 in autism spectrum disorder. *Nat Neurosci* 18 (2), 302-9.
- 662 104. Just, M.A. et al. (2012) Autism as a neural systems disorder: a theory of frontal-posterior  
663 underconnectivity. *Neurosci Biobehav Rev* 36 (4), 1292-313.
- 664 105. Schipul, S.E. et al. (2011) Inter-regional brain communication and its disturbance in autism.  
665 *Front Syst Neurosci* 5, 10.
- 666 106. Courchesne, E. et al. (2019) The ASD Living Biology: from cell proliferation to clinical phenotype.  
667 *Mol Psychiatry* 24 (1), 88-107.
- 668 107. Goldman, S.M. et al. (2014) Peptidoglycan recognition protein genes and risk of Parkinson's  
669 disease. *Mov Disord* 29 (9), 1171-80.
- 670 108. Eberl, G. and Lochner, M. (2009) The development of intestinal lymphoid tissues at the interface  
671 of self and microbiota. *Mucosal Immunol* 2 (6), 478-85.
- 672 109. Moore, R.E. and Townsend, S.D. (2019) Temporal development of the infant gut microbiome.  
673 *Open Biol* 9 (9), 190128.

674 [Figure legends](#)

675

676 [Figure 1. Biological signaling pathways and molecules involved in the microbiota-gut-brain](#)  
677 [axis](#). There are multiple direct and indirect pathways through which gut microbiota may  
678 influence the brain, including signals carried by neuronal circuits [e.g., bidirectional vagus  
679 nerve-to-brain communication, the enteric nervous system and neuropods; (1)], the  
680 production of bacterial fermentation metabolic by-products, such as short chain fatty acids  
681 [SCFAs; propionate, butyrate and acetate; (2)], tryptophan metabolites and  
682 neurotransmitters (3), release of cytokines by immune cells [A. Dendritic cell; B. B cell; C.  
683 Mast cell; D. T cell; (4)], and gut hormone signaling (5). Some of these molecules can activate  
684 the vagus nerve or reach the brain via systemic circulation, and directly affect brain  
685 functions. Activation of the hypothalamic-pituitary-adrenal (HPA) axis is characterized by the  
686 release of corticotropin-releasing hormone (CRH) from the paraventricular nucleus, which  
687 then stimulates the release of adrenocorticotrophic hormone (ACTH) from the anterior  
688 pituitary gland. ACTH then acts on the adrenal cortex to stimulate the production and  
689 release of glucocorticoids (corticosterone in rodents and cortisol in humans), which can have  
690 a major impact on gut physiology (e.g., modulating the intestinal epithelial barrier and  
691 immune responses), and gut microbiota composition (6). The gut microbiota has been  
692 shown to influence various neurodevelopmental processes such as microglial maturation  
693 and function, blood brain barrier formation and integrity, myelination and neurogenesis (7).

694

695 **Figure 2. Bacterial PGN location and structure.** **A.** Gram-positive bacteria display a multilayered PGN  
696 cell wall, which contains teichoic acids and often other polysaccharides, proteins and lipoproteins  
697 (not shown). In contrast, Gram-negative bacteria have a relatively thin PGN cell wall, surrounded by  
698 an outer membrane containing lipopolysaccharides (LPS). **B.** PGN is a polymer consisting of  $\beta$  (1-4)-  
699 linked N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc), with all lactyl groups of  
700 MurNAc substituted with stem peptides, typically containing four alternating L- and D-amino acids.  
701 The stem peptides from adjacent strands are often crosslinked, either directly or through short  
702 peptides. Shown are two examples of the general types of PGN, lysine-type PGN characteristic for  
703 cell walls in most Gram-positive bacteria and DAP-type PGN present in Gram-negative bacteria and a  
704 subset of Gram-positive bacteria. PGN motifs are recognized via a series of PRRs such as NOD-like  
705 receptors. For example, an intact MurNAc moiety is essential for Nod2 recognition, which is strongly  
706 activated by muramyl dipeptide (MDP). In contrast, the presence of the glycan moiety is not required  
707 for Nod1 recognition as iE-DAP or Tri-DAP are sufficient for the activation of this PRR. However, Nod1  
708 is also activated to meso-DAP-type PGN containing muramyl tripeptides (M-TriDAP) or tetrapeptides  
709 (M-TetraDAP). In addition, M-TriDAP modified by amidation of the meso-DAP residue (DAPNH<sub>2</sub>) have  
710 been shown activates Nod2 and not recognized by Nod1 receptor [31].

711

712

713

714

715

716

717 **Figure 3. Evidence from invertebrate and vertebrate models supporting a role of PGN in the**  
718 **crosstalk between microbial symbionts and their hosts.** **A.** Beneficial symbiotic relationship  
719 between the squid *Euprymna scolopes* and the luminescent bacteria *Vibrio fischeri*.  
720 Epithelial cells of the light organ of *E. scolopes* secrete mucus-containing peptidoglycan  
721 recognition protein 2 (PGRP2) that select *V. fischeri* from other bacterial species present in  
722 the water. *V. fischeri* enters through the pores into the ducts of the light organ and colonize  
723 the deep crypts, where they induce apoptosis and morphogenesis of the light organ (figure

724 modified from [52]). **B.** Development of isolated lymphoid follicles (ILFs) by commensal gut  
725 microbiota. Nod1 receptors in intestinal epithelial cells are activated by PGN released by the  
726 gut microbiota inducing the expression of CCL20 and  $\beta$ -defensin-3. These factors are CC  
727 chemokine receptor 6 (CCR6) agonists expressed on intestinal B cells and lymphoid tissue  
728 inducer (LTi) cells in cryptopatches. Activated CCR6 cause the recruitment of CCR6+ B cells to  
729 form immature ILFs. The development of immature ILFs into mature follicles require the  
730 tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) produced by dendritic cells. B cells from mature ILFs  
731 produce IgA that modulates the composition of the gut microbiota (figure modified from  
732 [108]). **C.** Gut microbiota primes the bone marrow-derived neutrophils. Meso-DAP-type PGN  
733 released by Gram-negative bacteria in the gut can be translocated into the systemic  
734 circulation and reach the neutrophils in the bone marrow. The activation of Nod1 receptor in  
735 the neutrophils result in their increased capacity to react against microorganisms (figure  
736 modified from [56]).

737

738

739

740

741

742

743

744

745

746 **Figure 4. Translocation of bacterial PGN from gut microbiota to the brain.** **A.** PGN motifs  
747 from the commensal gut microbiota disseminate systemically and can reach the brain. **B.**  
748 Schematic representation of blood brain barrier composed by endothelial cells of the brain  
749 capillary wall, astrocyte end-feet surrounding the capillary and pericytes embedded in the  
750 capillary basement membrane. PGN motifs can cross blood brain barrier and are sensed by

751 PRRs expressed in brain cells (neurons, oligodendrocytes and microglia). See main text for  
752 further details.

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770 [Figure 5. Schematic representation of the proposed PGN dissemination from maternal](#)  
771 [microbiota to the fetal brain.](#) **A.** PGN fragments derived from commensal maternal gut  
772 microbiota translocate from the gut lumen into the bloodstream and reach the placenta.  
773 PGN can transverse the placenta and enter the fetal brain, where it can affect key  
774 neurodevelopmental processes (e.g., proliferation, differentiation, synaptogenesis and  
775 myelination) via activation of PGN-sensing molecules of the innate immune system. **B.** PGN



776 signaling can be affected by host genetics (e.g., single nucleotide polymorphisms (SNP) and  
777 copy number variations (CNV) in genes coding for PGN sensing molecules and/or  
778 transporters) and external factors such as antibiotic exposure, maternal stress and mode of  
779 delivery. Optimal low PGN levels are needed for the typical brain development. However,  
780 too low or high PGN levels gives rise to atypical brain development.

781

782

783 **Box 1. Factors influencing the development of the infant microbiota**

784 During early postnatal life, the development of the infant gut microbiota follows successive  
785 waves of microbial exposures and colonization that is influenced by age-associated events  
786 such as dietary transitions (e.g., cessation of breastfeeding and the introduction of solid  
787 foods into the diet), leading to a more complex and diverse adult-like ecosystem around the  
788 first 2-3 years of age (see Ref. [109]). However, the exact age at which the toddler gut  
789 microbiota comes to resemble the adult pattern may vary depending upon the prenatal and  
790 neonatal history.

791 Several factors play an important role in shaping the development of the infant microbiota  
792 and potential functional outcomes including the mode of delivery (cesarean delivery vs.  
793 vaginal delivery), breastfeeding practices (breast milk vs. formula feeding) and use of  
794 antibiotic (see Refs. [8, 9]). In addition, other factors such as length of gestation (i.e. full-  
795 term vs. pre-term birth), nutritional status (under- and overnutrition), hospitalization and  
796 genetics can have a profound impact on neonatal microbial colonization trajectories. The  
797 fact that the assembly and maturation of the infant gut microbiota co-occurs in parallel with  
798 key neurodevelopmental process (e.g., myelination, synaptogenesis, synaptic refinement  
799 and acquisition of brain functions) has led to the realization that the early postnatal period  
800 represent not only a critical time-window in brain and microbial development, but also a key  
801 determinant period of health in later-life [8, 9].

802 **Clinician's Corner**

803 Traditionally, the translocation of bacterial products such as peptidoglycans (PGN) to the  
804 brain has mainly been considered in the context of infection and inflammation. However,  
805 the recent realization of the size and complexity of the human microbiome and its wide  
806 ranging impact on host physiology and development has triggered a reevaluation of the  
807 possible role of bacterial-derived products and metabolites from the non-pathogenic  
808 microbiota on host tissues, including brain development and behavior.

809

810 PGN from commensal microbiota are ubiquitously present in circulation and can cross the  
811 blood brain barrier. PGN-sensing molecules are highly expressed in the normal developing  
812 brain and their expression is highly sensitive to manipulations of the gut microbiota,  
813 including perinatal antibiotic exposure. Work from transgenic animal models implicate PGN-  
814 sensing molecules in the control of social behavior and anxiety.

815

816 PGN sensing molecules are expressed in the human placenta and represent an important  
817 mediator for microbiota-host communication at the maternal-fetal interface. Studies in  
818 rodents suggest that circulating PGN fragments from maternal gut microbiota can influence  
819 the fetal brain, and subsequent cognitive development.

820

821 From a clinical point of view, detection of PGN levels during the perinatal period could  
822 represent a new strategy to screen and identify infants and children at risk of  
823 neurodevelopmental and psychiatric disorders such as autism spectrum disorder.




824



825 At the genetic level, there is a need to explore potential associations between genetic  
826 polymorphisms in PGN-sensing molecules (e.g., peptidoglycan recognition proteins and Nod-  
827 like receptors) and neurodevelopmental disorders.




828



829


830









**A****B****Brain development**